MGMT and glioblastoma: Specifically, GBM cell lines such as LN18 and T98G overexpress elevated levels of O6-methylguanine-DNA methyltransferase (MGMT) and exhibit significant resistance to current FDA-approved alkylating agent, such as temozolomide [23,24].